Ken Griffin Eiger Bio Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.21 - $0.43 $2,101 - $4,303	10,008 New	10,008 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $42,423 - $311,108	41,592 Added 52.59%	120,680 $142,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $477,691 - $763,990	79,088 New	79,088 $595,000
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $299,683 - $479,377	58,532 Added 96.62%	119,109 $618,000
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $5.54 Million - $7.55 Million	-829,372 Reduced 93.19%	60,577 $405,000
Q1 2021 May 17, 2021	SELL	$8.44 - $12.66 $500,939 - $751,408	-59,353 Reduced 6.25%	889,949 $7.88 Million
Q4 2020 Feb 16, 2021	BUY	$7.98 - $12.29 $494,736 - $761,943	61,997 Added 6.99%	949,302 $11.7 Million
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $31,879 - $49,742	4,005 Added 0.45%	887,305 $7.22 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $162,097 - $401,340	30,018 Added 3.52%	883,300 $8.48 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $2.05 Million - $6.14 Million	417,929 Added 96.0%	853,282 $5.8 Million
Q4 2019 Feb 14, 2020	BUY	$9.77 - $15.66 $53,041 - $85,018	5,429 Added 1.26%	435,353 $6.49 Million
Q3 2019 Nov 14, 2019	BUY	$9.59 - $12.0 $1.26 Million - $1.57 Million	131,096 Added 43.87%	429,924 $4.41 Million
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $2.85 Million - $4.47 Million	298,828 New	298,828 $3.17 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.